LV009 injection for blood and lymph cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer has come back or did not respond to treatment, and it is a type of blood or lymph cancer that has a marker called CD19.
- You are generally well enough to be up and about (performance status 0-2), and your organs (liver, kidneys, heart, lungs) work well enough.
- You have enough immune cells (T cells) and blood cells (lymphocytes and platelets) in your blood.
- You have not had CAR-T cell therapy before, and your cancer has not spread to your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
This trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell non-Hodgkin’s lymphoma has come back or did not respond to standard treatments. It may help your immune system attack the cancer cells that carry a specific marker called CD19.
This trial tests a universal CAR-T cell therapy for patients with non-Hodgkin lymphoma whose cancer cells have CD19 on their surface. It might help if standard treatments have not worked.
This early-stage trial tests a new type of immune cell therapy (LVIVO-TaVec122) designed to fight back against B-cell lymphomas and leukemias that have stopped responding to previous treatments. The goal is to see if this therapy is safe and how well it works.
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.